540 related articles for article (PubMed ID: 29211042)
1. Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy.
Torphy RJ; Schulick RD; Zhu Y
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29211042
[TBL] [Abstract][Full Text] [Related]
2. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
[TBL] [Abstract][Full Text] [Related]
3. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
[TBL] [Abstract][Full Text] [Related]
4. Not All Immune Checkpoints Are Created Equal.
De Sousa Linhares A; Leitner J; Grabmeier-Pfistershammer K; Steinberger P
Front Immunol; 2018; 9():1909. PubMed ID: 30233564
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
6. Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy.
Wu B; Zhong C; Lang Q; Liang Z; Zhang Y; Zhao X; Yu Y; Zhang H; Xu F; Tian Y
J Exp Clin Cancer Res; 2021 Aug; 40(1):267. PubMed ID: 34433460
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy.
Rotte A; Jin JY; Lemaire V
Ann Oncol; 2018 Jan; 29(1):71-83. PubMed ID: 29069302
[TBL] [Abstract][Full Text] [Related]
8. Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).
Scutti JAB
Int J Oncol; 2018 Apr; 52(4):1041-1056. PubMed ID: 29484440
[TBL] [Abstract][Full Text] [Related]
9. Molecular Imaging of Immunotherapy Targets in Cancer.
Ehlerding EB; England CG; McNeel DG; Cai W
J Nucl Med; 2016 Oct; 57(10):1487-1492. PubMed ID: 27469363
[TBL] [Abstract][Full Text] [Related]
10. Recent developments and future challenges in immune checkpoint inhibitory cancer treatment.
Koster BD; de Gruijl TD; van den Eertwegh AJ
Curr Opin Oncol; 2015 Nov; 27(6):482-8. PubMed ID: 26352539
[TBL] [Abstract][Full Text] [Related]
11. [Immune-checkpoints: the new anti-cancer immunotherapies].
Ileana E; Champiat S; Soria JC
Bull Cancer; 2013 Jun; 100(6):601-10. PubMed ID: 23735730
[TBL] [Abstract][Full Text] [Related]
12. [Progress on tumor immune checkpoints and their inhibitors in tumor therapy].
Wang L; Bai L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Jul; 37(7):663-670. PubMed ID: 34140079
[TBL] [Abstract][Full Text] [Related]
13. Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors.
Catalano M; Shabani S; Venturini J; Ottanelli C; Voltolini L; Roviello G
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551630
[TBL] [Abstract][Full Text] [Related]
14. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.
Hahn AW; Gill DM; Pal SK; Agarwal N
Immunotherapy; 2017 Jun; 9(8):681-692. PubMed ID: 28653573
[TBL] [Abstract][Full Text] [Related]
15. TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action.
Du W; Yang M; Turner A; Xu C; Ferris RL; Huang J; Kane LP; Lu B
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28300768
[TBL] [Abstract][Full Text] [Related]
16. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.
Cai L; Li Y; Tan J; Xu L; Li Y
J Hematol Oncol; 2023 Sep; 16(1):101. PubMed ID: 37670328
[TBL] [Abstract][Full Text] [Related]
17. Emerging targets in cancer immunotherapy.
Burugu S; Dancsok AR; Nielsen TO
Semin Cancer Biol; 2018 Oct; 52(Pt 2):39-52. PubMed ID: 28987965
[TBL] [Abstract][Full Text] [Related]
18. The Features of Checkpoint Receptor-Ligand Interaction in Cancer and the Therapeutic Effectiveness of Their Inhibition.
Kuzevanova A; Apanovich N; Mansorunov D; Korotaeva A; Karpukhin A
Biomedicines; 2022 Aug; 10(9):. PubMed ID: 36140182
[TBL] [Abstract][Full Text] [Related]
19. [The "immune checkpoints", how does it work].
Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
[TBL] [Abstract][Full Text] [Related]
20. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
